Oncolog-Hematolog.ro 7

oncolog-hematolog
ro
oncologie
Bibliografie
with progressive colorectal cancer after irinotecan and fluorouracil- 32. Stocchi L., Nelson H., Sargent D.J. et al. Impact of surgical and patho-
leucovorin: interim results of aphase III trial. J Clin Oncol 2003;21:2059- logic variables in rectal cancer:a United States community and coop-
2069. erative group report. J Clin Oncol 2001;19:3895-3902.
9. Giacchetti S., Perpoint B., Zidani R. et al. PhaseII multicenter random- 33. Tepper J.E., O’Connell M.J., Niedzwiecki D. Et al. Impact of number of
ized trial of oxaliplatin addedto chronomodulated fluorouracil-leucov- nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol
orin asﬁrst-line treatment of metastatic colorectal cancer.J Clin Oncol 2001;19:157-163.
2000;18:136-147. 34. Compton C.C., Greene F.L. The staging of colorectal cancer: 2004 and
10. Hickish T., Boni C., Navarro M. et al. FOL-FOX4 as adjuvant treatment beyond. CA Cancer J Clin 2004;54:295-308.
for stage II colon can-cer: subpopulation data from the MOSAIC trial. J
35. Heald R.J., Moran B.J., Ryall R.D. et al. Rectal cancer: the Basing-
Oncol 2004; 22(suppl):14s. Abstract 3619.
stoke experience of total mesorectal excision, 1978-1997. Arch Surg
11. Saltz L., Rubin M., Hochster H. Et al. Cetuximab(IMC-C225) plus iri-
1998;133:894-899.
notecan (CPT-11) is active inCPT-11-refractory colorectal cancer (CRC)
36. Kapiteijn E., Marijnen C.A., Nagtegaal I.D. et al. Preoperative radio-
that expresses epidermal growth factor receptor (EGFR).Proc Am Soc
therapy combined with total mesorectal excision for resectable rectal
Clin Oncol. 2001; 20:3a.
cancer. N Engl J Med 2001;345:638-646.
12. Kabbinavar F., Hurwitz H.I., Fehrenbacher L. Et al. Phase II, random-
37. Schrag D., Cramer L.D., Bach P.B. etal. Inﬂuence of hospital proce-
ized trial comparing beva-cizumab plus fluorouracil (FU)/leucovorin
dure volume on outcomes following surgery for colon cancer. JAMA
(LV) with FU/LV alone in patients with metastatic col-orectal cancer. J
2000;284:3028-3035.
Clin Oncol 2003;21:60-65.
38. Meyerhardt J.A., Tepper J.E., Niedzwiecki D. Et al. Impact of hospital
13. Greene F.L., Page D.L., Fleming I.D. et al., eds. AJCC Cancer Staging
procedure volume on surgical operation and long-term outcomes in
Handbook. 6th ed. New York, NY: Springer; 2002.
high-risk curatively resected rectal cancer: ﬁndings from the Intergroup
14. Greene F.L., Stewart A.K., Norton H.J. A newTNM staging strategy for
0114 Study. J Clin Oncol 2004;22:166-174.
node-positive (stage III) cancer: an analysis of 50,042 patients. Ann Surg
39. Sobrero A., Guglielmi A., Grossi F. et al. Mechanism of action of fluo-
2002; 236:416-421.
ropyrimidines: relevance to the new developments in colorectal cancer
15. Greene F.L., Stewart A.K., Norton H.J. Newtumor-node-metastasis
chemotherapy. Semin Oncol 2000;27(Suppl 10):72-77.
staging strategy for node-positive (stage III) rectal cancer: an analysis. J
40. Higgins G.A., Humphrey E., Juler G. et al. Adjuvant chemotherapy in the
Clin Oncol 2004;22:1778-1784.
surgical treatment of large bowel cancer. Cancer 1976;38:1461-1467.
16. Meyerhardt J.A., Mayer R.J. Systemic therapy forcolorectal cancer. N
41. Higgins G.A., Donaldson R.C., Humphrey E.W. et al. Adjuvant therapy
Engl J Med 2005;352:476-487.
for large bowel cancer: update of Veterans Administration Surgical On-
17. O’Connell J.B., Maggard M.A., Ko C.Y. Coloncancer survival rates with
cology Group Trials. Surg Clin North Am 1981; 61:1311-1320.
the new American JointCommittee on Cancer sixth edition staging. J
42. Grossi C.E., Wolff W.I., Nealon T.F. Jr. et al. Intraluminal ﬂuorouracil
NatlCancer Inst 2004;96:1420-1425.
chemotherapy adjunct to surgical procedures for respectable carcino-
18. Compton C., Fenoglio-Preiser C.M., Pettigrew N., Fielding L.P. Ameri-
ma of the colon and rectum. Surg Gynecol Obstet 1977; 145:549-554.
can Joint Committee onCancer Prognostic Factors Consensus Confer-
43. Grage T.B., Moss S.E. Adjuvant chemotherapy in cancer of the colon
ence:Colorectal Working Group. Cancer 2000;88: 1739-1757.
and rectum: demonstration of effectiveness of prolonged 5-FU chemo-
19. Krasna M.J., Flancbaum L., Cody R.P. et al. Vascular and neural inva-
therapy in a prospectively controlled, randomized trial. Surg Clin North
sion in colorectal carcinoma. Incidence and prognostic signiﬁcance.
Am 1981;61:1321-1329.
Cancer 1988; 61:1018-1023.
44. Buyse M., Zeleniuch-Jacquotte A., Chalmers T.C. Adjuvant therapy of
20. Hampel H., Frankel W.L., Martin E. et al. Screening for the Lynch
colorectal cancer. Why we still don’t know. JAMA 1988;259:3571-3578.
syndrome (hereditary non-polyposis colorectal cancer). N Engl J Med
2005;352:1851-1860.
45. Taylor I., Machin D., Mullee M. Et al. A randomized controlled trial of
21. Shibata D., Reale M.A., Lavin P. Et al. The DCC protein and prognosis
adjuvant portal vein cytotoxic perfusion in colorectal cancer. Br J Surg
in colorectal cancer. N Engl J Med 1996; 335:1727-1732.
1985;72:359-363.
22. Hodgson D.C., Zhang W., Zaslavsky A.M. et al. Relation of hospital vol-
46. Wereldsma J.C., Bruggink E.D., Meijer W.S. et al. Adjuvant portal liver
ume to colostomy rates and survival for patients with rectal cancer. J
infusion in colorectal cancer with 5-ﬂuorouracil/heparin versus uroki-
Natl Cancer Inst 2003;95:708-716.
nase versus control. Results of a prospective randomized clinical trial
23. Wanebo H.J., Rao B., Pinsky C.M. et al. Preoperative carcinoembryonic
(colorectal adenocarcinoma trial I). Cancer 1990;65:425-432.
antigen level as a prognostic indicator in colorectal cancer. N Engl J
47. Beart R.W. Jr., Moertel C.G., Wieand H.S. et al. Adjuvant therapy for re-
Med 1978;299:448-451.
sectable colorectal carcinoma with ﬂuorouracil administered by portal
24. Wolmark N., Fisher B., Wieand H.S. et al. The prognostic signiﬁcance
vein infusion. A study of the Mayo Clinic and the North Central Cancer
of preoperative carcinoembryonic antigen levels in colorectal cancer.
Treatment Group. Arch Surg 1990;125:897-901.
Results from NSABP (National Surgical Adjuvant Breast and Bowel
48. Wolmark N., Rockette H., Wickerham D.L. et al. Adjuvant therapy of
Project) clinical trials. Ann Surg 1984; 199:375-382.
Dukes’A, B, and C adenocarcinoma of the colon with portal-vein fluo-
25. Moertel C.G., Fleming T.R., Macdonald J.S. et al. Intergroup study of
rouracil hepatic infusion: preliminary results of National Surgical Adju-
ﬂuorouracil plus levamisole as adjuvant therapy for stage II/Dukes’B2
vant Breast and Bowel Project Protocol C-02. J Clin Oncol 1990;8:1466-
colon cancer. J Clin Oncol 1995;13:2936-2943.
1475.
26. Gryfe R., Kim H., Hsieh E.T. et al. Tumor microsatellite instability and
49. Fielding L.P., Hittinger R., Grace R.H., Fry J.S. Randomised controlled
clinical outcome in young patients with colorectal cancer. N Engl J Med
trial of adjuvant chemotherapy by portal vein perfusion after curative
2000;342:69-77.
resection for colorectal adenocarcinoma. Lancet 1992; 340:502-506.
27. Watanabe T., Wu T.T., Catalano P.J. et al. Molecular predictors of
50. Long-term results of single course of adjuvant intraportal chemo-
survival after adjuvant chemotherapy for colon cancer. N Engl J Med
therapy for colorectal cancer. Swiss Group for Clinical Cancer Research
2001;344:1196-1206.
(SAKK). Lancet 1995;345:349-353.
28. Popat S., Houlston R.S. A systematic review and meta-analysis of
51. Portal vein chemotherapy for colorectal cancer: a meta-analysis of
the relationship between chromosome 18q genotype, DCC status and
4000 patients in 10 studies. Liver Infusion Meta-analysis Group. J Natl
colorectal cancer prognosis. Eur J Cancer 2005;41: 2060-2070.
Cancer Inst 1997;89:497-505.
29. Swanson R.S., Compton C.C., Stewart A.K., Bland K.I. The prognosis of
52. Bedikian A.Y., Valdivieso M., Mavligit G.M. et al. Sequential chemoim-
T3N0 colon cancer is dependent on the number of lymph nodes exam-
munotherapy of colorectal cancer: evaluation of methotrexate, Baker’s
ined. Ann Surg Oncol 2003;10:65-71. Antifol and levamisole. Cancer 1978;42:2169-2176.
30. Le Voyer T.E., Sigurdson E.R., Hanlon A.L. et al. Colon cancer survival 53. Buroker T.R., Moertel C.G., Fleming T.R. et al. A controlled evaluation
is associated with increasing number of lymph nodes analyzed: a sec- of recent approaches to biochemical modulation or enhancement of 5-
ondary survey of intergroup trial INT-0089. J Clin Oncol 2003;21:2912- ﬂuorouracil therapy in colorectal carcinoma. J Clin Oncol 1985;3:1624-
2919. 1631.
31. Berger A.C., Sigurdson E.R., LeVoyer T. et al. Colon cancer survival 54. Windle R., Bell P.R., Shaw D. Five year results of a randomized trial
is associated with decreasing ratio of metastatic to examined lymph of adjuvant 5-fluorouracil Adjuvant Treatment of Colorectal Cancer
nodes. J Clin Oncol 2005;23:8706-8712. 182CAA Cancer Journal for Clinicians.
pag. 20
Nr. 7 (2)/2009
Page 1 | Page 2 | Page 3 | Page 4 | Page 5 | Page 6 | Page 7 | Page 8 | Page 9 | Page 10 | Page 11 | Page 12 | Page 13 | Page 14 | Page 15 | Page 16 | Page 17 | Page 18 | Page 19 | Page 20 | Page 21 | Page 22 | Page 23 | Page 24 | Page 25 | Page 26 | Page 27 | Page 28 | Page 29 | Page 30 | Page 31 | Page 32 | Page 33 | Page 34 | Page 35 | Page 36 | Page 37 | Page 38 | Page 39 | Page 40 | Page 41 | Page 42 | Page 43 | Page 44 | Page 45 | Page 46 | Page 47 | Page 48 | Page 49 | Page 50 | Page 51 | Page 52 | Page 53 | Page 54 | Page 55 | Page 56 | Page 57 | Page 58 | Page 59 | Page 60 | Page 61 | Page 62 | Page 63 | Page 64 | Page 65 | Page 66 | Page 67 | Page 68